Clinical trial
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal…
NCT00004941 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00004941 |
|---|---|
| Title | Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Collaborators | Centocor, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | monoclonal antibody cA2 |
| Enrollment | 94 |
| Start date | Jul 1, 1996 |
| Completion | Jul 1, 1996 |
| First posted | Feb 25, 2000 |
| Last update posted | Mar 25, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: